Table 3. HCMV-specific immune... | American Society of Hematology

Table 3.

HCMV-specific immune reconstitution in 8 patients at more than 150 days after allogeneic SCT

Patient	Donor	HCMV serostatus (D/R)^3-150	Chronic GVHD	Immune suppression	HCMV infection^3-151		HCMV disease	Peptide-specific CD8⁺		Protein-specific CD4⁺ Count (n/μL)
Patient	Donor	HCMV serostatus (D/R)^3-150	Chronic GVHD	Immune suppression	Duration, wk	Peak viral load (GE/mL)	HCMV disease	HLA allele	Count (n/μL)	Protein-specific CD4⁺ Count (n/μL)
5^3-152	Sibl	+/+	Limited	Pred 0.1	3	3240	—	A2	9.6	ND
20	Sibl	+/+	No	CSA/pred 0.1	0	< 400	—	A2	7.6	8.3
21^3-153	Sibl	+/+	Limited	—	8	56 900	Late IP	A2	1.2	—
12	MM	+/+	Limited	—	9	ND	—	A2	52.5	—
15^3-152,^3-154	MUD	+/+	Limited	CSA	2	< 400	Late IP	A2	35.81	0.79
17	MUD	−/+	Limited	0.1	12	210 000	—	A1	—	1.51
22	MUD	+/−	Limited	CSA/pred 0.2	8	11 300	—	A2	5.45	ND
23^3-152	MUD	−/+	Limited	—	8	50 400	Late IP	A2	—	—

Patient	Donor	HCMV serostatus (D/R)^3-150	Chronic GVHD	Immune suppression	HCMV infection^3-151		HCMV disease	Peptide-specific CD8⁺		Protein-specific CD4⁺ Count (n/μL)
Patient	Donor	HCMV serostatus (D/R)^3-150	Chronic GVHD	Immune suppression	Duration, wk	Peak viral load (GE/mL)	HCMV disease	HLA allele	Count (n/μL)	Protein-specific CD4⁺ Count (n/μL)
5^3-152	Sibl	+/+	Limited	Pred 0.1	3	3240	—	A2	9.6	ND
20	Sibl	+/+	No	CSA/pred 0.1	0	< 400	—	A2	7.6	8.3
21^3-153	Sibl	+/+	Limited	—	8	56 900	Late IP	A2	1.2	—
12	MM	+/+	Limited	—	9	ND	—	A2	52.5	—
15^3-152,^3-154	MUD	+/+	Limited	CSA	2	< 400	Late IP	A2	35.81	0.79
17	MUD	−/+	Limited	0.1	12	210 000	—	A1	—	1.51
22	MUD	+/−	Limited	CSA/pred 0.2	8	11 300	—	A2	5.45	ND
23^3-152	MUD	−/+	Limited	—	8	50 400	Late IP	A2	—	—

HCMV indicates human cytomegalovirus; SCT, stem cell transplantation; GVHD, chronic graft-versus-host disease; GE, genome equivalents; Sibl, HLA-identical sibling; pred, prednisolone; ND, not done; CSA, cyclosporin A; IP, interstitial pneumonia; MM, HLA-nonidentical family member; and MUD, matched unrelated donor.

F3-150

HCMV serostatus as assessed by enzyme-linked immunosorbent assay in stem cell donor (D) and recipient (R).

F3-151

Duration indicates the weeks of viremia as assessed by the in-house polymerase chain reaction method before day 100 after SCT. Viral load was measured with a COBAS Amplicor HCMV monitor. The peak viral load before day 100 is indicated.

F3-152

Patients who received nonmyeloablative conditioning treatment.

F3-153

Patient who received CD34⁺-selected stem cells obtained with use of the CliniMACS system.

F3-154

This patient received donor lymphocytes for relapse of the underlying malignant disease. Severe GVHD subsequently developed and was treated with corticosteroids and OKT3. The patient later died from HCMV-induced pneumonia (Figure 4).

View Large

This Feature Is Available To Subscribers Only